CITY THERAPEUTICS, INC.
City Therapeutics, a clinical-stage RNAi biotech founded in July 2023 by Alnylam veterans including John Maraganore, filed an S-1 for an IPO on Nasdaq under ticker "CTY." The company has three disclosed programs: lead candidate CITY-FXI (Phase 1, targeting thromboembolic diseases), CITY-RBP4 (Stargardt disease, Phase 1 expected late 2026), and CITY-TFR2 (anemia of chronic disease, IND filing late 2026). The company has never generated product revenue and has only recently initiated its first clinical trial.
- Lead candidate CITY-FXI showed 85% FXI knockdown three weeks after a single 150 mg subcutaneous dose in Phase 1 SAD data.
- CITY-FXI Phase 2 trial in total knee arthroplasty expected to initiate in mid-2027.
- CITY-RBP4 for Stargardt disease filed for Phase 1 initiation in mid-2026; initial data expected mid-2027.
- CITY-TFR2 for anemia of chronic disease targets IND filing in late 2026 and Phase 1/2 start in early 2027.
- Strategic collaborations with Bausch + Lomb (July 2024) and Biogen (May 2025) for extrahepatic RNAi delivery in eye and CNS.
Price data unavailable.
A high-profile RNAi startup founded by the architect of Alnylam's commercial success is going public with three disclosed programs and early but promising Phase 1 data for its lead asset.
City joins a growing cohort of RNAi-focused biotechs going public, following the commercial validation of the modality by Alnylam's eight FDA-approved RNAi therapeutics. The pipeline targets large markets: thrombosis (~1 in 4 deaths worldwide), Stargardt disease (30,000+ U.S. patients, no approved
<
No product candidates have been approved; CITY-FXI is in early Phase 1 with no completed clinical trials. The City Platform and novel RNAi engineering approach are unproven and may not yield marketable products. The company has never generated product revenue and will require substantial additional
Get filings like this before the market reacts.
Real-time SEC filing alerts, AI summaries, and a free daily digest — plus portfolio tracking that ties filings to your positions.